Table 1 Eligibility criteria for comparison of EBMT registry to MC-FludT.14/L Trial II study patients.

From: Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

1. Patient age between 50 and 70 years

2. Karnofsky performance score of at least 60

3. Primary or secondary AML in complete remission or MDS†

4. Matched (i.e., HLA-identical) sibling donor or matched unrelated donor‡

5. First allogeneic hematopoietic cell transplantation

6. Peripheral blood or bone marrow stem cell graft source

  1. AML Acute myeloid leukemia, MDS Myelodysplastic syndrome, HLA human leucocyte antigen.
  2. †Regardless of WHO subtype or IPSS-R risk score.
  3. ‡Matched at least at HLA-loci A, B, C, DRB1, DQB1.
Back to article page